Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study of Risk-Reducing Salpingo-Oophorectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-Up of Select GOG-0199 Study Participants

NCT01139957 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT01139957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01139957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study of Risk-Reducing Salpingo-Oophorectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-Up of Select GOG-0199 Study Participants
Lead sponsor
Gynecologic Oncology Group
Phase
Observational
Overall status
Completed
Start date
June 7, 2010
Completion date
April 10, 2020
Enrollment
1,916 (estimated)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, fallopian tube carcinoma, ovarian neoplasm, primary peritoneal carcinoma